Iris melanoma

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 2, 2008, Pages 268-272

  Henderson, Evita ^a   Margo, Curtis E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IRIS DISEASE; IRIS MELANOMA; MELANOCYTE; MELANOMA; PROGNOSIS; RISK FACTOR; SHORT SURVEY;

HUMANS; IMMUNOHISTOCHEMISTRY; IRIS NEOPLASMS; MELANOMA; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 38949196734     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. Shields JA, Shields CL. Intraocular Tumors. A Text and Atlas. Philadelphia, Pa: WB Saunders; 1992:61-83.
2. Jensen OA, Prause JU. Malignant melanomas of the human uvea in Denmark 1943-1952: a clinical, histopathological and prognostic study. Acta Ophthalmol. 1963;75(suppl):17-78.
3. Kersten KC, Tse DT, Anderson R. Iris melanoma: nevus or malignancy? Surv Ophthalmol. 1985;29:423-433.
4. Geisse LH, Robertson DM. Iris melanoma. Am J Ophthalmol. 1985;99:638-648.
5. Artensen JJ, Green WR. Melanoma of the iris: report of 72 cases treated surgically. Ophthalmic Surg. 1975;6:23-37.
6. Ashton N, Wybar K. Primary tumors of the iris. Ophthalmologica. 1966;51:97-113.
7. Rones B, Zimmerman LE. The prognosis of primary tumors of the iris treated by iridectomy. Arch Ophthalmol. 1958;60:193-205.
8. Cleasby GW. Malignant melanoma of the iris. Arch Ophthalmol. 1958;60:403-417.
9. Jensen OA. Malignant melanoma of the iris: a 25-year-year analysis of Danish cases. Eur J Ophthalmol. 1993;3:181-188.
10. Davidorf DF. The melanoma controversy: a comparison of choroidal, cutaneous and iris melanomas. Surv Ophthalmol. 1981;25:373-377.
11. Rootman J, Gallagher RP. Color as a risk factor in iris melanoma. Am J Ophthalmol. 1984;98:558-561.
12. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanomas. Surv Ophthalmol. 1988;32:239-251.
13. Demirci H, Shields CL, Shields JA, Eagle RC Jr, Honavar SG. Diffuse iris melanoma: a report of 25 cases. Ophthalmology. 2002;109:1553-1560.
14. Conway RM, Chew T, Golchet P, et al. Ultrasound biomicroscopy: role in diagnosis and management in 130 consecutive patients evaluated for anterior segment tumours. Br J Ophthalmol. 2005;89:950-955.
15. Grossniklaus HE. Fine-needle aspiration biopsy of the iris. Arch Ophthalmol. 1992;110:969-976.
16. Shields CS, Manquez ME, Ehya H, et al. Fine-needle aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications. Ophthalmology. 2006;113:2080-2086.
17. Singh AD, Rennie IG, Seregard S, et al. Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol. 2004;49:419-428.
18. Cu-Unieng AB, Shields CL, Shields JA, Eagle RC Jr. Iris melanoma in ocular melanocytosis. Cornea. 1995;14:206-209.
19. Honavar SG, Sing AD, Shields CL, et al. Iris melanoma in a patient with neurofibromatosis. Surv Ophthalmol. 2000;45:231-236.
20. McLean IW, Burnier MN, Zimmerman LE, Jakobiec FA. Tumors of the Eye and Ocular Adnexa. Washington, DC: Armed Forces Institute of Pathology; 1993: 155-214. Atlas of Tumor Pathology; 3rd series, fascicle 12.
21. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502-509.
22. Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745-766.
23. Jakobiec FA, Silbert G. Are most iris "melanomas" really nevi? Arch Ophthalmol. 1981;99:2117-2132.
24. Grossniklaus HE, Oakman JH, Calhoun FP Jr, et al. Histopathology, morphometry, and nuclear DNA content of iris melanocyte lesions. Invest Ophthalmol Vis Sci. 1995;36:745-750.
25. Chowers I, Folberg R, Livni N, Pe'er J. Comparison of microcirculation patterns and MIB-1 immunoreactivitiy in iris and posterior uveal melanomas. Ophthalmology. 2001;108:367-371.
26. McLean IW. Prognostic features of uveal malignant melanoma. Ophthalmol Clin North Am. 1995;8:143-153.
27. Burnier MN Jr, McLean IW, Gamel JW. Immunohistochemical evaluation of uveal melanocytic tumors: expression of HMB-45- S-100 protein, and neuron-specific enolase. Cancer. 1991;68:809-814.
28. Iwamoto S, Burrows RC, Grossniklaus HE, et al. Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. Arch Ophthalmol. 2002;12:1625-1629.
29. Chowers I, Folberg R, Livni N, Pe'er J. p53 immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid. Curr Eye Res. 2002;24:105-108.
30. Conway RM, Chua WC, Qureshi C, Billson FA. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol. 2001;85:848-854.
31. Margo CE. Microscopic examination of surgical margins of intraocular tumors excised en bloc. Ophthalmic Surg Laser. 1998;29:692-694.
32. Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001;108:172-178.
33. Shields JJ, Shields CL. Hepatic metastases of diffuse iris melanoma 17 years after enucleation. Am J Ophthalmol. 1989;106:749-750.
34. Brown D, Boniuk M, Font RL. Diffuse malignant melanoma of iris with metastasis. Surv Ophthalmol. 1990;34:161-167.